Drug Profile
Research programme: infectious disease vaccines - Aeras/Okairos AG/University of Oxford
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aeras; Okairos AG; University of Oxford
- Class Parasitic vaccines; Tuberculosis vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections; Malaria; Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in Switzerland
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in United Kingdom
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in USA